original ) (raw )In Vitro Responsiveness of Glioma Cell Lines to Multimodality Treatment With Radiotherapy, Temozolomide, and Epidermal Growth Factor Receptor Inhibition With Cetuximab
C. Herold-mende , Juergen Debus
International Journal of Radiation Oncology*Biology*Physics, 2007
View PDFchevron_right
Epidermal Growth Factor Receptor Expression Modulates Antitumor Efficacy of Vandetanib or Cediranib Combined With Radiotherapy in Human Glioblastoma Xenografts
Adam Dicker
International Journal of Radiation Oncology*Biology*Physics, 2012
View PDFchevron_right
Epidermal growth factor receptor mutation status and Rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation
Yaacov Lawrence
2013
View PDFchevron_right
Future Perspectives of Enhancing the Therapeutic Efficacy of Epidermal Growth Factor Receptor Inhibition in Malignant Gliomas
Marc-Eric Halatsch
Novel Therapeutic Concepts in Targeting Glioma, 2012
View PDFchevron_right
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
John Suh
Journal of neuro- …, 2010
View PDFchevron_right
The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma
juan jose pineda castro
International journal of molecular sciences, 2018
View PDFchevron_right
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models
R. Grossman
Journal of Neuro-Oncology, 2013
View PDFchevron_right
Use of An Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response
Ajay Pandita
Clinical Cancer …, 2006
View PDFchevron_right
EGFR Amplified and Overexpressing Glioblastomas and Association with Better Response to Adjuvant Metronomic Temozolomide
Pietro Poliani
JNCI Journal of the National Cancer Institute, 2015
View PDFchevron_right
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy
David Gonda
Journal of Neuro-Oncology, 2012
View PDFchevron_right
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Andreas Unterberg
Molecular Cancer Research, 2009
View PDFchevron_right
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Philippe J Chollet
PloS one, 2016
View PDFchevron_right
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Kurt Jaeckle
Journal of Clinical Oncology, 2008
View PDFchevron_right
EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
Ekkehard Dikomey
Oncotarget, 2015
View PDFchevron_right
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma
Marie-france Poupon
Clinical Cancer …, 2009
View PDFchevron_right
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
Priya Kumthekar
Neuro-oncology, 2018
View PDFchevron_right
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
Enrique Moltó
British journal of cancer, 2009
View PDFchevron_right
Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
Marc-Eric Halatsch
Cancers, 2012
View PDFchevron_right
Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study
Christine Marosi
Journal of Neuro-Oncology, 2008
View PDFchevron_right
A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly-diagnosed glioblastoma patients
Eric Wong
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
View PDFchevron_right
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Daphne Haas-kogan , David Stokoe
Journal of Clinical Oncology, 2008
View PDFchevron_right
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
cecile Maire
CNS Drugs
View PDFchevron_right
Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WKGrowth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) ...
Rodney Luwor
Cancer Research
View PDFchevron_right
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
Martin Van Den Bent
European Journal of Cancer, 2010
View PDFchevron_right
MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor
Anna N Cvrljevic - Lipsanen , Hui Gan
International Journal of Radiation Oncology*Biology*Physics, 2010
View PDFchevron_right